Benjamin Cailes

Benjamin Cailes

Auto-generated profile, based on publicly available information

Benjamin Cailes

The University of Melbourne Clinical School, Austin Health, Department of Cardiology, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
BCBenjamin Cailes
Benjamin Cailes
EHEva-Louise Huber
Eva-Louise Huber
CBClaudia Brick
Claudia Brick
OFOmar Farouque
Omar Farouque
AMAvik Majumdar
Avik Majumdar
AKAnoop N. Koshy
Anoop N. Koshy
Cirrhotic cardiomyopathy (CCM) is an underrecognized risk factor for cardiac events in patients undergoing liver transplantation (LT). Blunted cardiac reserve (BCR) is an emerging indicator of CCM, although it has not been integrated into diagnostic guidelines. This study assesses post-transplant cardiac outcomes and mortality in patients with BCR compared to current CCM diagnostic guidelines, focusing on diastolic indices. Consecutive patients undergoing liver transplant assessment were included. Of 978 patients screened with dobutamine stress echocardiography between 2010-2023, 481 (58.0%) progressed to LT, with 183 (38.0%) meeting BCR criteria and 117 (24.3%) meeting existing CCM diagnostic criteria. Thirty (6.2%) patients suffered a 30-day major adverse cardiovascular event (MACE), and 92 patients (19.1%) died on long-term follow-up. Following multivariate regression analysis, BCR was the strongest independent risk factor for post-operative MACE (HR 2.57 (1.13-5.85), p=0.024), heart failure exacerbations (HR 6.93 (1.46-33.01), p=0.015), and 30-day mortality (HR 9.69 (1.04-92.33), p=0.049). Addition of BCR to the existing guidelines improved MACE prediction (HR 5.81 (1.71-19.76) vs 2.59 (1.15-5.87), p=0.006), with a net reclassification improvement index of 41.9% (p=0.004) compared to existing guidelines alone. These results support the integration of a cardiac reserve assessment into CCM diagnostic criteria, and use in risk stratification of patients undergoing LT.

3 June 2025 in Liver Transplantation
Verified
Journal Article
Open access
BCBenjamin Cailes
Benjamin Cailes
NKNuman Kutaiba
Numan Kutaiba
OFOmar Farouque
Omar Farouque
AMAvik Majumdar
Avik Majumdar
TRThalys Sampaio Rodrigues
Thalys Sampaio Rodrigues
AKAnoop N. Koshy
Anoop N. Koshy
Cardiovascular (CV) disease is a leading cause of postoperative mortality following liver transplantation (LT). The presence of abdominal aortic calcification (AAC) has been linked to CV events in the general population. We sought to investigate whether AAC on routine pre-transplant CT can improve the prediction of coronary artery disease, post-LT major adverse cardiovascular events (MACEs) or long-term mortality. Of 461 patients undergoing LT between 2010 and 2018, 318 were included in the analysis, among whom 81 had also undergone computed tomography coronary angiography. The extent of AAC was quantified with high AAC defined as a calcium score ≥500. High AAC was identified in 84/318 (26.4%) and demonstrated moderate correlation with coronary artery calcium score (CACS) ( r =0.52, p <0.001). Thirty-two MACE events occurred in 28 patients (8.8%) within 30 days. High AAC was a strong independent predictor of moderate-to-severe coronary disease on CT coronary angiography (OR 12.6, 95% CI 1.5–103.0, p =0.02). It was also associated with a significantly increased risk of 30-day MACE (OR 2.34, 95% CI 1.08–5.05, p =0.03) and long-term mortality (HR 2.45, 95% CI 1.18–5.06, p =0.02). Following multivariate analysis adjusting for pertinent CV risk factors, high AAC remained a strong independent predictor of MACE (OR 3.10, 95% CI 1.27–7.60, p =0.02). Addition of AAC to the Revised Cardiac Risk Index significantly improved model fit for predicting MACE outcomes ( p <0.01), while the absence of heavy AAC ruled out moderate-to-severe disease on CT coronary angiography with a negative predictive value of 97.0%. High AAC on routine CT scans was associated with a 3-fold increased risk of 30-day MACE post-LT and improved CV risk prediction compared to traditional indices. Quantification of AAC may offer a simple method of improving CV risk assessment in these patients.

3 November 2025 in Heart, Lung and Circulation
Verified
Journal Article
Open access
CBClaudia R. Brick
Claudia R. Brick
BCBenjamin Cailes
Benjamin Cailes
AMAvik Majumdar
Avik Majumdar
ATAdam Testro
Adam Testro
MSMarie Sinclair
Marie Sinclair
AKAnoop N. Koshy
Anoop N. Koshy
Cardiac comorbidities in patients with cirrhosis are common yet frequently under-recognised. Cirrhotic cardiomyopathy, a subclinical state of cardiac dysfunction, is emerging as a critical contributor to major adverse cardiac events in this patient population, as well as liver events such as hepatorenal syndrome. The increasing prevalence of patients with metabolic dysfunction-associated steatotic liver disease and concomitant coronary artery disease also poses significant management challenges for these patients. This review focuses on the considerable burden of cardiac disease in patients with cirrhosis, most notably in those undergoing assessment for liver transplantation. Our findings highlight the importance of early detection and the use of appropriate management strategies to enhance post-transplant cardiovascular outcomes.

28 February 2024 in JHEP Reports
Verified
Journal Article
Open access
BCBenjamin Cailes
Benjamin Cailes
OFOmar Farouque
Omar Farouque
AMAvik Majumdar
Avik Majumdar
AKAnoop N. Koshy
Anoop N. Koshy

15 May 2026 in Heart, Lung and Circulation
Verified
Journal Article
Open access
JCJames N. Cameron
James N. Cameron
BCBenjamin Cailes
Benjamin Cailes
TLTerase F. Lancefield
Terase F. Lancefield
JTJames Theuerle
James Theuerle
AKAnoop N. Koshy
Anoop N. Koshy
JYJulian Yeoh
Julian Yeoh
Previous reports of transcatheter aortic valve implantation (TAVI) in adults ≥90 years emphasise procedural success and survival. Whether nonagenarians experience clinically meaningful, sustained improvements in patient-reported outcomes, and how frailty and multimorbidity may modify these benefits, remains uncertain. We performed an exploratory single-centre retrospective cohort study of consecutive nonagenarians undergoing TAVI (January 2019 - 31 October 2024). EuroQol 5-Dimensions 3-Level (EQ-5D-3L) (including Visual Analogue Scale, VAS) and the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) Summary Score were collected at baseline, 30 days and 12 months. Responders were defined using a ≥10-point minimally important difference. Deterioration was any negative pre- to 12-month change. Frailty was stratified into three prespecified Clinical Frailty Scale (CFS) categories: 1-3 (fit to managing well), 4-5 (vulnerable to mildly frail), and 6-9 (moderately to severely frail/terminally ill). Of 26 nonagenarians, 19 met inclusion criteria. Most were mildly-moderately frail (CFS 3-5: n=18; CFS 6: n=1). Median 30-day changes were +25 (IQR 10-38) for EQ-5D VAS (exact sign test p=0.001) and +39 (30-50) for KCCQ-12 (p<0.001), with gains largely sustained at 12-months (EQ-5D VAS p=0.096; KCCQ-12 p<0.001). At 12-months, 13/18 (72%) were EQ-5D VAS responders and 17/18 (94%) KCCQ-12 responders. Responder proportions were highest in less frail strata, noting CFS 6-9 contained a single patient. EQ-5D-3L problem burden improved across all domains, especially Mobility (p=0.002) and Usual activities (p=0.012). Twelve-month survival was 94% (18/19). In this single-centre nonagenarian cohort, we observed 30-day improvements in symptoms and function following TAVI that were maintained to 12 months. Observed changes appeared smaller with greater frailty and multimorbidity, and higher comorbidity burden coincided with a higher probability of deterioration. Findings should be interpreted as exploratory and hypothesis-generating.

24 June 2019 in Heart, Lung and Circulation
Verified
Journal Article
Open access
PDF file
AKAnoop N. Koshy
Anoop N. Koshy
BCB. Cailes
B. Cailes
ATAdam Testro
Adam Testro
JRJ. Ramchand
J. Ramchand
JSJ. Sajeev
J. Sajeev
OFOmar Farouque
Omar Farouque
Background: The role of cardiac dysfunction in the genesis of hepatorenal syndrome (HRS) is poorly understood. We studied cardiovascular haemodynamics in HRS and assessed whether a diminished cardiac reserve with stress testing predicted the development of HRS. Methods: Consecutive patients without known cardiac disease undergoing liver transplant workup with dobutamine stress echocardiogram (DSE) were included. Cardiac output (CO) was measured at baseline and during low-dose dobutamine infusion at 10 μg/kg/min. HRS was diagnosed using guideline-based criteria. Results: Overall, 560 patients underwent DSE of whom 488 were included following preliminary assessment. There were 64 (13.1%) patients with established HRS. The HRS cohort had higher baseline CO (8.0 ± 2 vs 6.9 ± 2 L/min; p < 0.001) but demonstrated a blunted response to low-dose dobutamine (ΔCO 29.2 ± 22% vs 44.4 ± 32%, p < 0.001) driven by inotropic incompetence. Optimal cut-point for % ΔCO in HRS patients was determined to be <25%, which was used to define a low cardiac reserve. Among the 424 patients without HRS initially, 85 (20.0%) developed HRS over a mean follow-up of 1.5 years. A significantly higher proportion with low cardiac reserve developed HRS [47 (55.0%) vs 38 (11.2%); p < 0.001]. After adjusting for clinical and echocardiographic covariates in a Cox model, low cardiac reserve remained the strongest predictor for development of HRS (HR 3.9; 95% CI 2.2–7.0; p < 0.001). Conclusion: A low cardiac reserve was an independent predictor for development of HRS. Assessment of cardiac reserve with DSE may provide a novel non-invasive marker of risk for developing HRS in patients with advanced liver disease.